

## MINNESOTA Diabetes Data &amp; Forecasts



State Total Population Forecasts	2015	2020	2025	2030
Entire Population	5,668,200	5,900,800	6,108,800	6,306,100
Prediabetes	1,508,500	1,622,200	1,729,600	1,787,900
Diagnosed diabetes	334,400	412,300	479,900	534,900
Undiagnosed diabetes	149,800	175,400	193,700	204,600
Total with diabetes (diagnosed and undiagnosed)	484,200	587,700	673,600	739,500
<b>Complications:</b>				
Visual impairment	54,800	65,600	74,100	80,200
Renal failure	800	950	1,070	1,150
Leg amputations	690	780	840	860
Annual deaths attributable to diabetes	3,600	4,240	4,690	4,950
Total annual cost (2015 dollars)	\$5.3 B	\$6.3 B	\$7.2 B	\$7.9 B
Annual medical costs	\$4.0 B	\$4.8 B	\$5.5 B	\$6.0 B
Annual nonmedical costs	\$1.3 B	\$1.5 B	\$1.7 B	\$1.9 B

State Senior Population Forecasts	2015	2020	2025	2030
Population 65 and older	774,400	910,000	1,036,100	1,193,100
Prediabetes	394,900	464,100	528,400	608,500
Diagnosed diabetes	146,400	172,000	195,800	225,500
Undiagnosed diabetes	54,200	63,700	72,500	83,500
Total with diabetes (diagnosed and undiagnosed)	200,600	235,700	268,400	309,000
<b>Complications:</b>				
Visual impairment	27,400	31,300	34,800	39,000
Renal failure	450	510	560	630
Leg amputations	340	370	390	410
Annual deaths attributable to diabetes	2,480	2,840	3,050	3,120
Total annual cost (2015 dollars)	\$2.6 B	\$3.0 B	\$3.4 B	\$3.9 B
Annual medical costs	\$2.4 B	\$2.8 B	\$3.2 B	\$3.7 B
Annual nonmedical costs	\$0.2 B	\$0.2 B	\$0.2 B	\$0.2 B

These forecasts are based on the latest available national diabetes data, including U.S Census Bureau population projections, the CDC National Diabetes Statistics Report, 2014, CDC diabetes morbidity trend reports, CDC's latest diabetes prevalence projections to 2050 and Dall, et al. "The Economic Burden of Elevated Blood Glucose Levels in 2012: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes," *Diabetes Care* 2014;37:3172-3179. These forecasts assume a steady, but conservative, reduction in the number of people with complications due to better awareness of the risks of diabetes, earlier screening and intervention, and more effective therapies.

For details and references on the Institute for Alternative Futures Diabetes 2030 Forecasting Model Methodology, visit [www.altfutures.org/diabetes2030](http://www.altfutures.org/diabetes2030).

Research funded by Novo Nordisk Inc.